1-8 of 8
Pietro Taverna
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C005: TP53 wildtype status can predict sensitivity to XPO1 inhibitors in Patient-Derived Cancer Models

Marie Maloof, Andrea Ellero, Pietro Taverna, Christopher J Walker
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C005.
https://doi.org/10.1158/1535-7163.TARG-23-C005
Published: 01 December 2023
View article titled, Abstract C005: <em>TP53</em> wildtype status can predict sensitivity to XPO1 inhibitors in Patient-Derived Cancer Models
Journal Articles

Abstract C083: Profiling of PDK1 inhibitor SNS-510 shows potent activity in hematologic and solid tumor cancer models and identifies CDKN2A-mutated cancers as potential targets with enhanced sensitivity

Pietro Taverna, Stig Hansen, Jeff Iwig, Gene Jamieson, Judy A Fox
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C083.
https://doi.org/10.1158/1535-7163.TARG-19-C083
Published: 01 December 2019
View article titled, Abstract C083: Profiling of PDK1 inhibitor SNS-510 shows potent activity in hematologic and solid tumor cancer models and identifies CDKN2A-mutated cancers as potential targets with enhanced sensitivity
Journal Articles

Abstract A256: Epigenetic priming with novel hypomethylating agent SGI-110 improved antitumor activity of CTLA-4 blockade in a syngenic mouse model.

Alessia Covre, Carolina Fazio, Hugues Nicolay, Giulia Parisi, Pietro Taverna, Mohammad Azab, Sandra Coral, Michele Maio
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A256.
https://doi.org/10.1158/1535-7163.TARG-13-A256
Published: 01 November 2013
View article titled, Abstract A256: Epigenetic priming with novel hypomethylating agent SGI-110 improved antitumor activity of CTLA-4 blockade in a syngenic mouse model.
Journal Articles

The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

Daniel L. Menezes, Pietro Taverna, Michael R. Jensen, Tinya Abrams, Darrin Stuart, Guoying Karen Yu, David Duhl, Timothy Machajewski, William R. Sellers, Nancy K. Pryer, Zhenhai Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 730–739.
https://doi.org/10.1158/1535-7163.MCT-11-0667
Published: 06 March 2012
View article titled, The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Abstract B272: The novel PIM kinase inhibitor SGI‐1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma

Devalingam Mahalingam, Ernest Medina, Ronan T. Swords, Kevin R. Kelly, David Bearss, Gavin Choy, Pietro Taverna, Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B272.
https://doi.org/10.1158/1535-7163.TARG-09-B272
Published: 10 December 2009
View article titled, Abstract B272: The novel PIM kinase inhibitor SGI‐1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma
Journal Articles

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes

Shannon M. Mumenthaler, Patricia Y.B. Ng, Amanda Hodge, David Bearss, Gregory Berk, Sarath Kanekal, Sanjeev Redkar, Pietro Taverna, David B. Agus, Anjali Jain
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (10): 2882–2893.
https://doi.org/10.1158/1535-7163.MCT-09-0293
Published: 12 October 2009
View article titled, Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
Open the PDF for Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes in another window
Journal Articles

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

Erica C. VanderPorten, Pietro Taverna, Jennifer N. Hogan, Marcus D. Ballinger, W. Michael Flanagan, Raymond V. Fucini
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (4): 930–939.
https://doi.org/10.1158/1535-7163.MCT-08-0754
Published: 16 April 2009
View article titled, The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model
Open the PDF for The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model in another window
Includes: Supplementary data
Journal Articles

SNS-032 has potent antitumor activity in vivo against human leukemia and multiple myeloma xenografts

Mamatha Reddy, Jennifer Arbitrario, Jeffrey Jones, Jeffrey Silverman, Anthony Howlett, Pietro Taverna
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A258.
Published: 01 November 2007
View article titled, SNS-032 has potent antitumor activity <em>in vivo</em> against human leukemia and multiple myeloma xenografts